Skip to contentA
Aptevo Therapeutics Inc.
A
APVOAptevo Therapeutics Inc. Q3 2022 · 10-Q
Revenue$0.00$0.00derived−100.0% vs Q3 2021 Net Income-$7.64M-$7.64MN/M vs Q3 2021 EPS Diluted-$1.50-$1.50N/M vs Q3 2021 Operating Income-$7,784,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aptevo Therapeutics Inc. · CIK 1671584 · Engraved from SEC EDGAR
Operating Cash Flowderived-$6,896,000N/M Free Cash Flowderived-$6,900,000N/M ended Sep 30, 2022 · filed Nov 10, 2022 · 41 d after period end